Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.

Maldonado L, Brait M, Izumchenko E, Begum S, Chatterjee A, Sen T, Loyo M, Barbosa A, Poeta ML, Makarev E, Zhavoronkov A, Fazio VM, Angioli R, Rabitti C, Ongenaert M, Van Criekinge W, Noordhuis MG, de Graeff P, Wisman GBA, van der Zee AGJ, Hoque MO.

Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.

PMID:
29964205
2.

Tobacco and alcohol-induced epigenetic changes in oral carcinoma.

Ghantous Y, Schussel JL, Brait M.

Curr Opin Oncol. 2018 May;30(3):152-158. doi: 10.1097/CCO.0000000000000444. Review.

3.

Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma.

Wysocki PT, Westra WH, Sidransky D, Brait M.

Oral Oncol. 2017 Nov;74:192-193. doi: 10.1016/j.oraloncology.2017.09.013. Epub 2017 Sep 20. No abstract available.

4.

MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients.

Martinelli CMDS, Lengert AVH, Cárcano FM, Silva ECA, Brait M, Lopes LF, Vidal DO.

Oncotarget. 2016 Aug 10;8(31):50608-50617. doi: 10.18632/oncotarget.11167. eCollection 2017 Aug 1.

5.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

6.

Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease.

Datta S, Nam HS, Hayashi M, Maldonado L, Goldberg R, Brait M, Sidransky D, Illei P, Baras A, Vij N, Hoque MO.

Respir Med. 2017 Mar;124:72-78. doi: 10.1016/j.rmed.2017.02.011. Epub 2017 Feb 17.

7.

Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.

Brait M, Banerjee M, Maldonado L, Ooki A, Loyo M, Guida E, Izumchenko E, Mangold L, Humphreys E, Rosenbaum E, Partin A, Sidransky D, Hoque MO.

Oncotarget. 2017 Feb 28;8(9):15431-15440. doi: 10.18632/oncotarget.14873.

8.

Comparative mutational landscape analysis of patient-derived tumour xenografts.

Brait M, Izumchenko E, Kagohara LT, Long S, Wysocki PT, Faherty B, Fertig EJ, Khor TO, Bruckheimer E, Baia G, Ciznadija D, Sloma I, Ben-Zvi I, Paz K, Sidransky D.

Br J Cancer. 2017 Feb 14;116(4):515-523. doi: 10.1038/bjc.2016.450. Epub 2017 Jan 24.

9.

Adenoid cystic carcinoma: emerging role of translocations and gene fusions.

Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D, Brait M.

Oncotarget. 2016 Oct 4;7(40):66239-66254. doi: 10.18632/oncotarget.11288. Review.

10.

Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening.

Ling S, Rettig EM, Tan M, Chang X, Wang Z, Brait M, Bishop JA, Fertig EJ, Considine M, Wick MJ, Ha PK.

Int J Oncol. 2016 Jul;49(1):225-34. doi: 10.3892/ijo.2016.3532. Epub 2016 May 18.

11.

High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing.

Duberow DP, Brait M, Hoque MO, Theodorescu D, Sidransky D, Dasgupta S, Mathies RA.

J Mol Med (Berl). 2016 Sep;94(9):1015-24. doi: 10.1007/s00109-016-1407-2. Epub 2016 Mar 31.

PMID:
27030170
12.

Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration.

Wang Z, Ling S, Rettig E, Sobel R, Tan M, Fertig EJ, Considine M, El-Naggar AK, Brait M, Fakhry C, Ha PK.

Oral Oncol. 2015 Dec;51(12):1120-5. doi: 10.1016/j.oraloncology.2015.09.010. Epub 2015 Oct 17.

13.

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.

Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, Marchionni L, Agrawal N, Ravi R, Jones S, Hoque MO, Westra WH, Sidransky D.

Nat Commun. 2015 Sep 16;6:8258. doi: 10.1038/ncomms9258.

14.

An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation.

Begum S, Hayashi M, Ogawa T, Jabboure FJ, Brait M, Izumchenko E, Tabak S, Ahrendt SA, Westra WH, Koch W, Sidransky D, Hoque MO.

Sci Rep. 2015 Aug 28;5:13236. doi: 10.1038/srep13236.

15.

Epigenetic silencing of S100A2 in bladder and head and neck cancers.

Lee J, Wysocki PT, Topaloglu O, Maldonado L, Brait M, Begum S, Moon D, Kim MS, Califano JA, Sidransky D, Hoque MO, Moon C.

Oncoscience. 2015 Mar 16;2(4):410-8. eCollection 2015.

16.

Milk derived colloid as a novel drug delivery carrier for breast cancer.

Hayashi M, Silanikove N, Chang X, Ravi R, Pham V, Baia G, Paz K, Brait M, Koch WM, Sidransky D.

Cancer Biol Ther. 2015;16(8):1184-93. doi: 10.1080/15384047.2015.1056416. Erratum in: Cancer Biol Ther. 2015;16(10):1567.

17.

Calcium calmodulin dependent kinase kinase 2 - a novel therapeutic target for gastric adenocarcinoma.

Subbannayya Y, Syed N, Barbhuiya MA, Raja R, Marimuthu A, Sahasrabuddhe N, Pinto SM, Manda SS, Renuse S, Manju HC, Zameer MA, Sharma J, Brait M, Srikumar K, Roa JC, Vijaya Kumar M, Kumar KV, Prasad TS, Ramaswamy G, Kumar RV, Pandey A, Gowda H, Chatterjee A.

Cancer Biol Ther. 2015;16(2):336-45. doi: 10.4161/15384047.2014.972264.

18.

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO.

Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13.

19.

Notch1 mutations are drivers of oral tumorigenesis.

Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, McCord CL, Riley DR, Angiuoli SV, Velculescu VE, Jiang WW, Sidransky D.

Cancer Prev Res (Phila). 2015 Apr;8(4):277-286. doi: 10.1158/1940-6207.CAPR-14-0257. Epub 2014 Nov 18.

20.

Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile.

Kagohara LT, Schussel JL, Subbannayya T, Sahasrabuddhe N, Lebron C, Brait M, Maldonado L, Valle BL, Pirini F, Jahuira M, Lopez J, Letelier P, Brebi-Mieville P, Ili C, Pandey A, Chatterjee A, Sidransky D, Guerrero-Preston R.

Future Oncol. 2015;11(2):233-49. doi: 10.2217/fon.14.165. Epub 2014 Jul 28.

21.

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.

Maldonado L, Brait M, Michailidi C, Munari E, Driscoll T, Schultz L, Bivalacqua T, Schoenberg M, Sidransky D, Netto GJ, Hoque MO.

Oncotarget. 2014 Jul 30;5(14):5218-33.

22.

Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.

Hayashi M, Bernert H, Kagohara LT, Maldonado L, Brait M, Schoenberg M, Bivalacqua T, Netto GJ, Koch W, Sidransky D, Hoque MO.

Oncotarget. 2014 May 30;5(10):3350-61.

23.

The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.

Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque MO, Ling S, Bedi A, Sidransky D.

Cancer Res. 2014 Jul 15;74(14):3995-4005. doi: 10.1158/0008-5472.CAN-14-0110. Epub 2014 May 15. Erratum in: Cancer Res. 2014 Sep 1;74(17):4950-1.

24.

Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials.

Michailidi C, Soudry E, Brait M, Maldonado L, Jaffe A, Ili-Gangas C, Brebi-Mieville P, Perez J, Kim MS, Zhong X, Yang Q, Valle B, Meltzer SJ, Torbenson M, Esteller M, Sidransky D, Guerrero-Preston R.

Gastroenterol Res Pract. 2014;2014:597164. doi: 10.1155/2014/597164. Epub 2014 Apr 17.

25.

GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.

Maldonado L, Brait M, Loyo M, Sullenberger L, Wang K, Peskoe SB, Rosenbaum E, Howard R, Toubaji A, Albadine R, Netto GJ, Hoque MO, Platz EA, Sidransky D.

J Urol. 2014 Nov;192(5):1542-8. doi: 10.1016/j.juro.2014.04.082. Epub 2014 Apr 21.

26.

Expression microarray analysis reveals alternative splicing of LAMA3 and DST genes in head and neck squamous cell carcinoma.

Li R, Ochs MF, Ahn SM, Hennessey P, Tan M, Soudry E, Gaykalova DA, Uemura M, Brait M, Shao C, Westra W, Bishop J, Fertig EJ, Califano JA.

PLoS One. 2014 Mar 27;9(3):e91263. doi: 10.1371/journal.pone.0091263. eCollection 2014.

27.

Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

Brebi P, Maldonado L, Noordhuis MG, Ili C, Leal P, Garcia P, Brait M, Ribas J, Michailidi C, Perez J, Soudry E, Tapia O, Guzman P, Muñoz S, Van Neste L, Van Criekinge W, Irizarry R, Sidransky D, Roa JC, Guerrero-Preston R.

Epigenetics. 2014 Feb;9(2):308-17. doi: 10.4161/epi.27120. Epub 2013 Nov 15.

28.

Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, Marchionni L, de Graeff P, van der Zee AG, Wisman GB, Sidransky D, Hoque MO.

PLoS One. 2013 Sep 27;8(9):e70878. doi: 10.1371/journal.pone.0070878. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/5d2e13d4-cb4e-44b1-a836-dff9b4144b5b. Noordhuis, Maartje [corrected to Noordhuis, Maartje G]. PLoS One. 2013;8(10). doi:10.1371/annotation/ccd51e37-fdf3-466e-b79f-2c390df9ab28.

29.

EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions.

Schussel J, Zhou XC, Zhang Z, Pattani K, Bermudez F, Jean-Charles G, McCaffrey T, Padhya T, Phelan J, Spivakovsky S, Brait M, Li R, Bowne HY, Goldberg JD, Rolnitzky L, Robbins M, Kerr AR, Sirois D, Califano JA.

Clin Cancer Res. 2013 Jun 15;19(12):3268-75. doi: 10.1158/1078-0432.CCR-12-3496. Epub 2013 May 1.

30.

Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Brait M, Munari E, LeBron C, Noordhuis MG, Begum S, Michailidi C, Gonzalez-Roibon N, Maldonado L, Sen T, Guerrero-Preston R, Cope L, Parrella P, Fazio VM, Ha PK, Netto GJ, Sidransky D, Hoque MO.

Cell Cycle. 2013 Apr 1;12(7):1058-70. doi: 10.4161/cc.24050. Epub 2013 Feb 22.

31.

Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.

Brait M, Ling S, Nagpal JK, Chang X, Park HL, Lee J, Okamura J, Yamashita K, Sidransky D, Kim MS.

PLoS One. 2012;7(9):e44951. doi: 10.1371/journal.pone.0044951. Epub 2012 Sep 27.

32.

SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.

Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, Westra WH, Hoque MO, Yang P, Yi JE, Lam S, Gazdar AF, Fisher PB, Jen J, Sidransky D.

J Mol Med (Berl). 2013 Mar;91(3):381-93. doi: 10.1007/s00109-012-0955-3. Epub 2012 Sep 12.

33.

Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.

Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO.

Epigenetics. 2012 Jul;7(7):710-9. doi: 10.4161/epi.20524. Epub 2012 Jul 1.

34.

Detection of Merkel cell virus and correlation with histologic presence of Merkel cell carcinoma in sentinel lymph nodes.

Loyo M, Schussel J, Colantuoni E, Califano J, Brait M, Kang S, Koch WM, Sidransky D, Westra WH, Taube JM.

Br J Cancer. 2012 Mar 27;106(7):1314-9. doi: 10.1038/bjc.2012.73. Epub 2012 Mar 13.

35.

Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer.

Okamura J, Huang Y, Moon D, Brait M, Chang X, Kim MS.

Cancer Biol Ther. 2012 Feb 1;13(3):148-55. doi: 10.4161/cbt.13.3.18695. Epub 2012 Feb 1.

36.

AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.

Rosenbaum E, Begum S, Brait M, Zahurak M, Maldonado L, Mangold LA, Eisenberger MA, Epstein JI, Partin AW, Sidransky D, Hoque MO.

Prostate. 2012 Jul 1;72(10):1133-9. doi: 10.1002/pros.22461. Epub 2011 Nov 29.

37.

DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma.

Brait M, Maldonado L, Begum S, Loyo M, Wehle D, Tavora FF, Looijenga LH, Kowalski J, Zhang Z, Rosenbaum E, Halachmi S, Netto GJ, Hoque MO.

Br J Cancer. 2012 Jan 17;106(2):414-23. doi: 10.1038/bjc.2011.468. Epub 2011 Nov 8.

38.

Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.

Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, Chang S, Brait M, Jiang WW, Kim MM, Claybourne Q, Goldenberg D, Khan Z, Khan T, Westra WH, Sidransky D, Koch W, Califano JA.

Clin Cancer Res. 2011 Jul 15;17(14):4782-9. doi: 10.1158/1078-0432.CCR-11-0324. Epub 2011 May 31.

39.

An epigenetic marker panel for detection of lung cancer using cell-free serum DNA.

Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO, Sidransky D.

Clin Cancer Res. 2011 Jul 1;17(13):4494-503. doi: 10.1158/1078-0432.CCR-10-3436. Epub 2011 May 24.

40.

Cancer epigenetics: above and beyond.

Brait M, Sidransky D.

Toxicol Mech Methods. 2011 May;21(4):275-88. doi: 10.3109/15376516.2011.562671. Review.

41.

Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays.

LeBron C, Pal P, Brait M, Dasgupta S, Guerrero-Preston R, Looijenga LH, Kowalski J, Netto G, Hoque MO.

Genomics. 2011 Jun;97(6):341-9. doi: 10.1016/j.ygeno.2011.02.011. Epub 2011 Mar 2.

42.

DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation.

Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, Ratovitski E, Sidransky D.

Cancer Res. 2011 Feb 1;71(3):1167-76. doi: 10.1158/0008-5472.CAN-10-1481. Epub 2011 Jan 25.

43.

Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.

Hoque MO, Brait M, Rosenbaum E, Poeta ML, Pal P, Begum S, Dasgupta S, Carvalho AL, Ahrendt SA, Westra WH, Sidransky D.

J Thorac Oncol. 2010 Dec;5(12):1887-93. doi: 10.1097/JTO.0b013e3181f77a53. Erratum in: J Thorac Oncol. 2011 Feb;6(2):409.

44.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

45.

Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR.

Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D.

Clin Cancer Res. 2010 Jul 1;16(13):3463-72. doi: 10.1158/1078-0432.CCR-09-3304. Epub 2010 Jun 30.

46.

A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma.

Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, Califano JA, Liégeois NJ, Begum S, Westra WH, Hoque MO, Tao Q, Sidransky D.

Int J Cancer. 2011 Mar 15;128(6):1393-403. doi: 10.1002/ijc.25443.

47.

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V.

Cancer Res. 2010 Mar 15;70(6):2274-84. doi: 10.1158/0008-5472.CAN-09-2661. Epub 2010 Mar 2.

48.

KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.

Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, Huang P, Khan Z, Khan T, Ostrow KL, Brait M, Hoque MO, Liegeois NJ, Sidransky D, Koch W, Califano JA.

Int J Cancer. 2010 Nov 15;127(10):2351-9. doi: 10.1002/ijc.25248.

49.

Association between lifestyle factors and CpG island methylation in a cancer-free population.

Brait M, Ford JG, Papaiahgari S, Garza MA, Lee JI, Loyo M, Maldonado L, Begum S, McCaffrey L, Howerton M, Sidransky D, Emerson MR, Ahmed S, Williams CD, Hoque MO.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2984-91. doi: 10.1158/1055-9965.EPI-08-1245. Epub 2009 Oct 27.

50.

Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model.

Luangsay S, Wittamer V, Bondue B, De Henau O, Rouger L, Brait M, Franssen JD, de Nadai P, Huaux F, Parmentier M.

J Immunol. 2009 Nov 15;183(10):6489-99. doi: 10.4049/jimmunol.0901037. Epub 2009 Oct 19.

Supplemental Content

Support Center